BR0315417A - Derivados 1-acil-pirrolidina para o tratamento de infecções virais - Google Patents
Derivados 1-acil-pirrolidina para o tratamento de infecções viraisInfo
- Publication number
- BR0315417A BR0315417A BR0315417-3A BR0315417A BR0315417A BR 0315417 A BR0315417 A BR 0315417A BR 0315417 A BR0315417 A BR 0315417A BR 0315417 A BR0315417 A BR 0315417A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- alkyl
- viral infections
- aryl
- pyrrolidine derivatives
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0224774A GB0224774D0 (en) | 2002-10-24 | 2002-10-24 | Compounds |
| GB0229470A GB0229470D0 (en) | 2002-12-18 | 2002-12-18 | Compounds |
| GB0317141A GB0317141D0 (en) | 2003-07-22 | 2003-07-22 | Compounds |
| PCT/EP2003/011813 WO2004037818A1 (en) | 2002-10-24 | 2003-10-22 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0315417A true BR0315417A (pt) | 2005-08-16 |
Family
ID=32180212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0315417-3A BR0315417A (pt) | 2002-10-24 | 2003-10-22 | Derivados 1-acil-pirrolidina para o tratamento de infecções virais |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7304087B2 (enExample) |
| EP (1) | EP1554274B1 (enExample) |
| JP (1) | JP2006506455A (enExample) |
| KR (1) | KR20050057670A (enExample) |
| AR (1) | AR041816A1 (enExample) |
| AT (1) | ATE418554T1 (enExample) |
| AU (1) | AU2003276172A1 (enExample) |
| BR (1) | BR0315417A (enExample) |
| CA (1) | CA2503471A1 (enExample) |
| CO (1) | CO5550450A2 (enExample) |
| DE (1) | DE60325498D1 (enExample) |
| IS (1) | IS7851A (enExample) |
| MA (1) | MA27524A1 (enExample) |
| MX (1) | MXPA05004435A (enExample) |
| NO (1) | NO20052472L (enExample) |
| PL (1) | PL376454A1 (enExample) |
| TW (1) | TW200418848A (enExample) |
| WO (1) | WO2004037818A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304494D0 (en) * | 2003-02-27 | 2003-04-02 | Glaxo Group Ltd | Compounds |
| GB0408995D0 (en) * | 2004-04-22 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| GB0423673D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| GB0423672D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| WO2006050035A1 (en) | 2004-10-29 | 2006-05-11 | Schering Corporation | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| GB0519486D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519478D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519485D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519488D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| WO2008106166A2 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| EP2272832A4 (en) | 2008-04-28 | 2011-09-07 | Asahi Kasei Pharma Corp | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| BRPI0917458A2 (pt) | 2008-08-11 | 2015-12-01 | Glaxosmithkline Llc | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto |
| CN102176911B (zh) | 2008-08-11 | 2014-12-10 | 葛兰素史密丝克莱恩有限责任公司 | 新的腺嘌呤衍生物 |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| RS53745B1 (sr) | 2010-02-10 | 2015-06-30 | Glaxosmithkline Llc | 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
| ES2917887T3 (es) | 2014-11-13 | 2022-07-12 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US20220251079A1 (en) | 2019-05-16 | 2022-08-11 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| JP2022533390A (ja) | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| EP1051104B1 (en) | 1998-01-26 | 2008-04-09 | Massachusetts Institute Of Technology | Fluorescence imaging endoscope |
| WO1999054299A1 (en) | 1998-04-23 | 1999-10-28 | Abbott Laboratories | Pyrrolidines as inhibitors of neuraminidases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1118287B1 (de) * | 2000-01-21 | 2004-11-24 | Alois Ing. Sampl | Steckbares Regalsystem |
| EP1278743A4 (en) | 2000-05-05 | 2003-05-14 | Smithkline Beecham Corp | NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES |
| JP2004536779A (ja) | 2000-11-20 | 2004-12-09 | サイオス インコーポレイテッド | ｐ３８キナーゼのインドール型阻害剤 |
| JP2005511574A (ja) | 2001-10-26 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド |
| WO2003037893A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| US20060167702A1 (en) | 2002-10-28 | 2006-07-27 | Pierre-Paul Jodoin | Method of preventing theft to vehicles using intensive marking |
-
2003
- 2003-10-22 TW TW092129213A patent/TW200418848A/zh unknown
- 2003-10-22 DE DE60325498T patent/DE60325498D1/de not_active Expired - Fee Related
- 2003-10-22 CA CA002503471A patent/CA2503471A1/en not_active Abandoned
- 2003-10-22 PL PL03376454A patent/PL376454A1/xx not_active Application Discontinuation
- 2003-10-22 EP EP03809322A patent/EP1554274B1/en not_active Expired - Lifetime
- 2003-10-22 AU AU2003276172A patent/AU2003276172A1/en not_active Abandoned
- 2003-10-22 WO PCT/EP2003/011813 patent/WO2004037818A1/en not_active Ceased
- 2003-10-22 AT AT03809322T patent/ATE418554T1/de not_active IP Right Cessation
- 2003-10-22 MX MXPA05004435A patent/MXPA05004435A/es unknown
- 2003-10-22 KR KR1020057006957A patent/KR20050057670A/ko not_active Withdrawn
- 2003-10-22 BR BR0315417-3A patent/BR0315417A/pt not_active IP Right Cessation
- 2003-10-22 US US10/531,884 patent/US7304087B2/en not_active Expired - Fee Related
- 2003-10-22 AR ARP030103852A patent/AR041816A1/es not_active Application Discontinuation
- 2003-10-22 JP JP2005501534A patent/JP2006506455A/ja not_active Withdrawn
-
2005
- 2005-04-25 CO CO05038997A patent/CO5550450A2/es not_active Application Discontinuation
- 2005-05-06 MA MA28263A patent/MA27524A1/fr unknown
- 2005-05-19 IS IS7851A patent/IS7851A/is unknown
- 2005-05-23 NO NO20052472A patent/NO20052472L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5550450A2 (es) | 2005-08-31 |
| WO2004037818A1 (en) | 2004-05-06 |
| AU2003276172A1 (en) | 2004-05-13 |
| MA27524A1 (fr) | 2005-09-01 |
| PL376454A1 (en) | 2005-12-27 |
| US20060258720A1 (en) | 2006-11-16 |
| CA2503471A1 (en) | 2004-05-06 |
| DE60325498D1 (de) | 2009-02-05 |
| US7304087B2 (en) | 2007-12-04 |
| MXPA05004435A (es) | 2005-07-26 |
| EP1554274A1 (en) | 2005-07-20 |
| KR20050057670A (ko) | 2005-06-16 |
| NO20052472L (no) | 2005-05-23 |
| AR041816A1 (es) | 2005-06-01 |
| ATE418554T1 (de) | 2009-01-15 |
| IS7851A (is) | 2005-05-19 |
| JP2006506455A (ja) | 2006-02-23 |
| EP1554274B1 (en) | 2008-12-24 |
| TW200418848A (en) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007008616D1 (de) | Verfahren zur herstellung von 4'-azidocytidinderivaten | |
| BR0312129A (pt) | Derivados de espiroindolinapiperidina | |
| NO20052472L (no) | 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner. | |
| NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
| MEP24608A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
| ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
| DK1265606T3 (da) | Celleadhæsionsinhibitorer | |
| ATE291923T1 (de) | Veränderter faktor viii | |
| IS7533A (is) | Lifrarbólgu C-veirutálmar | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| NO20044807L (no) | Heratitt C virus inhibitorer | |
| ATE423122T1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
| HRP20050263B1 (hr) | Derivati pirolidina kao inhibitori maob | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| MX2007004914A (es) | Compuestos de acido 4-metoximetil-pirrolidina-2-carboxilico y sus derivados como inhibidores del virus de hepatitis c. | |
| MA30904B1 (fr) | Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90 | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| HRP20070549T3 (en) | Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems | |
| BR0314860A (pt) | Derivados de pirazol | |
| BR0313000A (pt) | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente | |
| NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
| DE602005010607D1 (de) | Zyklosporinanalog | |
| DE60003671D1 (de) | Halo-derivate von 9-deoxo-9a-aza-9a-homerythromycin a | |
| ATE386741T1 (de) | Pyrazolamide zur behandlung von hiv-infektionen | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |